Olema Oncology is a cancer medicines company dedicated to impacting breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a differentiated oral medicine known as a complete estrogen receptor antagonist (CERAN) initially in development for metastatic breast cancer. Our pipeline also includes OP-3136, a potent, selective oral inhibitor of the KAT6 pathway. At Olema, we are building a focused team committed to our mission with intention and clarity. Working alongside a talented, passionate group of leaders and advisors, we strive to create better medicines that aim to help patients feel better, longer. For more information, visit us at www.olema.com.
Company Details
- Employees
- 140
- Founded
- -
- Address
- 780 Brannan St, San Francisco,california 94103,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://olema.com
- Keywords
- pharmaceuticals, biotechnology, drug development, oncology, breast cancer, nuclear receptors, small molecules.
- HQ
- San Francisco, California
Olema Oncology Questions
Olema Oncology's website is http://olema.com
Olema Oncology's LinkedIn profile is https://www.linkedin.com/company/olema-oncology
Olema Oncology has
140 employees.
View email and phone details for 140
employees at Olema Oncology.
Olema Oncology's industry is
Biotechnology Research
Olema Oncology's top competitors are
Bridgebio,
Alx Oncology,
Alnylam Pharmaceuticals,
Arcus Biosciences,
Mirum Pharmaceuticals, Inc.,
Revolution Medicines,
Vera Therapeutics, Inc.,
Corcept Therapeutics,
Rain Oncology,
Vertex Pharmaceuticals.
Olema Oncology's categories are Biotechnology Research
Olema Oncology's founding year is 2007
